The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nédellec, S.
Right arrow Articles by Youinou, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nédellec, S.
Right arrow Articles by Youinou, P.
The Journal of Immunology, 2005, 174: 3749-3756.
Copyright © 2005 by The American Association of Immunologists

B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients 1

Steven Nédellec2,*, Yves Renaudineau2,*, Anne Bordron*, Christian Berthou*, Nina Porakishvili{dagger}, Peter M. Lydyard{dagger}, Jacques-Olivier Pers* and Pierre Youinou3,*

* Institut de Synergie des Sciences et de la Santé, Brest University Medical School, Brest, France; and {dagger} Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, London, United Kingdom

On the basis of responses to surface IgM (sIgM) cross-linking, B cells from 41 patients with B-chronic lymphocytic leukemia were categorized as 15 nonresponders (group I) and 26 responders (group II). The latter cases were subclassified as those seven where proliferation was induced (subgroup IIa) and the remaining 19 in whom apoptosis occurred (subgroup IIa). Signal disruption in group I was confirmed by the absence of Ca2+ mobilization. Activation of PI3K was constitutive in subgroup IIa, but not in subgroup IIb, and that of Akt induced by anti-µ in subgroup IIa, but not in subgroup IIb. Among the MAPK, ERK was more highly activated relative to p38 in subgroup IIa, whereas activation of p38 predominated over that of ERK in subgroup IIb. For subgroup IIb cells, based on tyrosine phosphorylation and translocation into lipid rafts, sIgM signaling was shown to be enhanced by Zap70. The different consequences of signaling through sIgM were associated with biological prognosis indicators. These included high levels of CD38, lack of mutations in the IgVH chain genes, preferential usage of full-length CD79b, and severe clinical stage. Thus, modification of sIgM-induced signaling could be a therapeutic approach.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Mankai, A. Bordron, Y. Renaudineau, C. Martins-Carvalho, S. Takahashi, I. Ghedira, C. Berthou, and P. Youinou
Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells
Cancer Res., September 15, 2008; 68(18): 7512 - 7519.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Muzio, B. Apollonio, C. Scielzo, M. Frenquelli, I. Vandoni, V. Boussiotis, F. Caligaris-Cappio, and P. Ghia
Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy
Blood, July 1, 2008; 112(1): 188 - 195.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
G. Cutrona, M. Colombo, S. Matis, M. Fabbi, M. Spriano, V. Callea, E. Vigna, M. Gentile, S. Zupo, N. Chiorazzi, et al.
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells
Haematologica, March 1, 2008; 93(3): 413 - 422.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Deaglio, T. Vaisitti, R. Billington, L. Bergui, P. Omede', A. A. Genazzani, and F. Malavasi
CD38/CD19: a lipid raft-dependent signaling complex in human B cells
Blood, June 15, 2007; 109(12): 5390 - 5398.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. T. Abrams, T. Lakum, K. Lin, G. M. Jones, A. T. Treweeke, M. Farahani, M. Hughes, M. Zuzel, and J. R. Slupsky
B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase C{beta}II
Blood, February 1, 2007; 109(3): 1193 - 1201.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Barragan, M. de Frias, D. Iglesias-Serret, C. Campas, E. Castano, A. F. Santidrian, L. Coll-Mulet, A. M. Cosialls, A. Domingo, G. Pons, et al.
Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}
J. Leukoc. Biol., December 1, 2006; 80(6): 1473 - 1479.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Gustafsson, B. Christensson, B. Sander, and J. Flygare
Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-Methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma
Mol. Pharmacol., November 1, 2006; 70(5): 1612 - 1620.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Jahrsdorfer, S. E. Blackwell, J. E. Wooldridge, J. Huang, M. W. Andreski, L. S. Jacobus, C. M. Taylor, and G. J. Weiner
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation
Blood, October 15, 2006; 108(8): 2712 - 2719.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P.-A. Deglesne, N. Chevallier, R. Letestu, F. Baran-Marszak, T. Beitar, C. Salanoubat, L. Sanhes, J. Nataf, C. Roger, N. Varin-Blank, et al.
Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of zap70 expression.
Cancer Res., July 15, 2006; 66(14): 7158 - 7166.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.